alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 626–650 of 701 studies in Mild cognitive impairment (page 26 of 29) · 27,380 in the whole library · How the 0–100 score works

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Other subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 12,859 studies have no institution on record and are not counted here.

What “Mild cognitive impairment” covers

Mild cognitive impairment — The stage between normal ageing and dementia: who progresses, who doesn't, and what predicts it.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Moderating role of triglycerides in the relationship between amyloid-β, hippocampal atrophy, and cognitive decline in mild cognitive impairment and early Alzheimer’s disease

✓ Peer-reviewed alzhub usefulness score 39 out of 100. Frontiers in Aging Neuroscience 2025-08-22

These findings highlight hippocampal atrophy as a key pathway linking Aβ burden to cognitive impairment. 4 key findings →

Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Mild cognitive impairment and everyday function: evidence of reduced speed in performing instrumental activities of daily living

✓ Peer-reviewed alzhub usefulness score 38 out of 100. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry 2008-05-01

Future research should address the question of whether performance-based functional measures, as well as simple queries regarding whether functional activities take longer than usual to complete, may improve the prediction of future cognitive decline and disease progression among those individuals in whom MCI represents impending dementia. 1 key finding →

Design: cross-sectional Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Dynamic changes in PET amyloid and FDG imaging at different stages of Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Neurobiology of aging 2010-08-04

In this study 5 patients with mild cognitive impairment (MCI) and 9 Alzheimer's disease (AD) patients underwent respectively 3- and 5-year follow-up positron emission tomography (PET) studies with N-methyl [(11)C] 2-(4-methylaminophenyl)-6-hydroxy-benzothiazole ((11)C-PIB) and (18)F-fluorodeoxyglucose ((18)F-FDG) to understand the time courses in AD disease processes. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source

Multimodal magnetic resonance imaging analysis of early mild cognitive impairment

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Journal of Alzheimer s Disease 2025-03-03

BackgroundEarly mild cognitive impairment (EMCI) represents a prodromal stage of dementia, and early detection is crucial for delaying dementia progression. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Revealing heterogeneity in mild cognitive impairment based on individualized structural covariance network

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Alzheimer s Research & Therapy 2025-05-15

In the ADNI dataset, MCI patients exhibited significant alterations in structural covariance edges, mainly involving the hippocampus, parahippocampal gyrus, and amygdala. 5 key findings →

Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Research progress of multimodal biomarkers in the early diagnosis of mild cognitive impairment in Parkinson’s disease

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Frontiers in Neurology 2025-08-29

Parkinson's disease (PD), as a common neurodegenerative disorder, its associated mild cognitive impairment (PD-mild cognitive impairment, PD-MCI) is a key prodromal stage in the progression to PD-dementia (PDD). 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Electroencephalography‐based signatures of cognitive resilience in individuals with stable mild cognitive impairment despite carrying a high‐risk for progression to dementia

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Alzheimer s & Dementia Translational Research & Clinical Interventions 2025-10-01

Compared with sMCI-resilient subjects, cMCI individuals exhibited increased frontal delta power, reduced posterior alpha power, and an elevated delta/alpha ratio in the right temporal region, consistent with cortical dysfunction. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Individualized prediction of transition from subjective cognitive decline to mild cognitive impairment based on multimodal MRI: a 10-year follow-up study

✓ Peer-reviewed alzhub usefulness score 38 out of 100. The Journal of Prevention of Alzheimer s Disease 2026-01-01

The model incorporating age, brain volume, functional, and radiomics features demonstrated the highest predictive performance for SCD progression in training (C-index: 0.962; 95 % CI: 0.95-0.98) and testing (C-index: 0.911; 95 % CI: 0.861-0.968) sets. 5 key findings →

Participants: 89 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Tau‐related reduction of glucose metabolism in mild cognitive impairment occurs independently of APOE ε4 genotype and is influenced by Aβ

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Alzheimer s & Dementia 2025-02-01

We found cortical regions where a reduced glucose metabolism was maximally correlated with distributed patterns of tau, accounting for the effect of Aβ and APOE ε4 genotype. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Beyond the Clock: Exploring Multimodal Behavior Markers of Mild Cognitive Impairment in Older Adults during Clock Drawing Test

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Proceedings of the ACM on Interactive Mobile Wearable and Ubiquitous Technologies 2025-12-02

Early detection of Mild Cognitive Impairment (MCI) offers a critical window for intervention before progression to dementia. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Improved cognitive function, efficiency, saccadic eye movement, and depressive symptoms in mild cognitive impairment with transcranial photobiomodulation

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Journal of Alzheimer s Disease 2025-07-24

These findings provide preliminary evidence that tPBM may effectively improve neuropsychological, physiological, and psychological outcomes in individuals with MCI. 4 key findings →

Participants: 25 Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Multimodal fusion model for diagnosing mild cognitive impairment in unilateral middle cerebral artery steno-occlusive disease

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Frontiers in Aging Neuroscience 2025-02-12

Based on the fusion of the topological features of the multimodal FBN and SBN, the accuracy for the diagnosis of MCI in patients with unilateral MCA steno-occlusive disease reached 90.00%. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Lateralization of the Aberrant Amplitude of Low-Frequency Fluctuation within the Default Mode Network in Patients with Mild Cognitive Impairment

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Academic Radiology 2025-01-15

The DMN is the highest coverage of brain network regarding changes in local brain activity in patients with MCI. 4 key findings →

Participants: 36 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Growth-associated protein 43 is associated with faster functional decline among amyloid-positive individuals with objectively defined subtle cognitive decline and mild cognitive impairment

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Neuropsychology 2025-03-01

The CU- group had lower baseline GAP-43 than all Aβ+ groups, but not the other Aβ- groups. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Alzheimer's Disease: Past, Present, and Future

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Journal of the International Neuropsychological Society : JINS 2017-10-01

Although dementia has been described in ancient texts over many centuries (e.g., "Be kind to your father, even if his mind fail him." - Old Testament: Sirach 3:12), our knowledge of its underlying causes is little more than a century old. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source

Emotional Recognition: A Comparative Study of People with Mild Cognitive Impairment and Alzheimer’s Disease Self-Report with Caregiver Perspectives

✓ Peer-reviewed alzhub usefulness score 37 out of 100. Journal of Geriatric Psychiatry and Neurology 2025-05-06

Participants across all groups showed significant differences in cognition and functionality. 5 key findings →

Participants: 141 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

The Role of Magnetic Resonance Spectroscopy ( MRS ), Diffusion‐Tensor‐Imaging ( DTI ) and Structural MRI in the Alzheimer's Disease and Mild Cognitive Impairment Diagnosis: A Review

✓ Peer-reviewed alzhub usefulness score 37 out of 100. Journal of Magnetic Resonance Imaging 2026-03-19

Alzheimer's disease (AD) is one of the most common neurological disorders affecting older adults, with approximately 7.2 million cases only in the United States. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed